Endo Pharmaceuticals and Bioniche Life Sciences Inc., today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin™. The trial is a randomized, active-controlled, open-label, multi-center study with a blinded endpoint assessment designed to compare Urocidin™ with mitomycin C in the intravesical treatment of patients with BCG recurrent or refractory non-muscle-invasive bladder cancer.
It is estimated that 450 patients will be enrolled for this new trial at approximately 120 clinical sites worldwide.
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients